Teplizumab Expansion Redefines Early Type 1 Diabetes Intervention, With Rachael Sood, NP
The FDA has approved an expanded indication for teplizumab-mzwv (Tzield) to delay the onset of stage 3 type 1 diabetes in children as young as 1 year of age diagnosed with stage 2 disease, extending the therapy's reach from its prior lower age limit of …